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Summary 
 
Comprehensive and sustained optimal care for HIV-infected patients can now be achieved in 
resource-constrained settings thanks to the sustainability of programs providing antiretroviral 
therapy. However the primary goals of HIV virological suppression and improved survival 
need to be accompanied by a substantial improvement in patient’s experience with HIV care 
and treatment. An assessment of both patient’s quality of life and perceived toxicity and 
symptoms should now be systematically integrated into HIV clinical research in resource-
constrained countries. This will allow treatment strategies aimed at optimizing the durability 
of response to antiretroviral therapy in these settings to be properly evaluated and compared. 
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The current scale-up of antiretroviral therapy (ART) in resource-constrained settings presents 
an unprecedented opportunity to radically reduce the burden of AIDS by improving survival 
rates and ensuring the virological control of HIV infection (1). ART access has transformed 
HIV into a chronic disease, but the burden of associated side-effects makes the sustainability 
of long–life treatment questionable. Despite these therapeutic progresses, stigma is 
frequently experienced by HIV-infected patients and has an adverse impact on health 
behaviours such as adherence and systematic condom use (2, 3).   
 
The routine follow-up of HIV-infected patients in resource-constrained settings is solely 
based on a non-optimal set of clinical and biological indicators aimed at monitoring ART 
efficacy. This latter however is highly dependent on adherence, which in turn is mainly 
influenced by patients’ perceptions of treatment experience (4). Patient experience with 
treatment can be measured either by generic (5) or HIV-specific (6) quality of life scales, or 
by other indicators of perceived health such as the HIV symptom index (7). Quality of life 
assessment is not only aimed at evaluating individual well-being, but also has public health 
purposes as high quality of life scores can positively influence health behaviours. Indeed, 
self-reported symptoms are associated with non-adherence to ART in both high- and low-
income countries (8-10). Similarly, poor perceived health has been shown to be a major 
correlate of unprotected sex among HIV-positive patients in Europe (11, 12), and a similar 
relationship was recently shown in West-Africa (13). 
 
In high-income countries, a wide variety of powerful ART regimens is available and the 
assessment of quality of life in clinical research is becoming an additional criterion to guide 
providers in selecting the best treatment option. For instance, in a recent trial comparing 
Lopinavir monotherapy with Lopinavir associated triple therapy (10), the number of self-
reported symptoms was found to be an important discriminatory measure as it revealed 
major differences in patient well-being. Similarly, a significant improvement in quality of life 
scores has been reported in patients switching from enfuvirtide to raltegravir (14). While 
several trials comparing ART regimens are ongoing in resource-constrained settings, the 
lack of data collection of patient reported outcomes in such trials could have a serious 
influence on decisions regarding the best treatment options to take when different treatment 
strategies show similar efficacy. 
 
To tackle this issue, there are at least three major reasons justifying the implementation of 
research on quality of life issues in resource-constrained settings. First, it is now conceivable 
that comprehensive and sustained optimal care can be achieved thanks to the sustainability 
of ART programs in such settings (15). It is therefore crucial to aim not only at achieving 
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virological suppression and improving survival, but also at optimizing patient perceived 
health. Second, the recently released WHO guidelines stress that, in resource-constrained 
settings, ART should be initiated among all HIV-infected patients with a CD4 count below 
350 cells/ml (16). Similarly, all pregnant and breastfeeding women in these settings should 
now be offered ART to both improve maternal health and prevent mother-to-child 
transmission of HIV (17, 18). Hence, an increasing proportion of patients will soon be on ART 
without having had any experience of symptomatic HIV disease. In this context, research on 
therapeutic strategies which are able to guarantee both efficacy and improvement in quality 
of life is now urgently required. Third, mathematical models have recently shown that an 
intervention based on annual universal HIV screening followed by immediate ART initiation 
for all those infected would dramatically reduce HIV incidence in a generalised epidemic 
setting (19). One cannot seriously expect this intervention to be widely implemented without 
an adequate prior ascertainment of both the public and individual benefits. For this reason, 
quality of life assessment should be introduced in forthcoming population based trials aimed 
at evaluating this "treatment as prevention" hypothesis.  
 
Tools aimed at measuring quality of life and other patient reported outcomes in the context of 
HIV infection were initially designed for high-income settings. There are no major 
methodological barriers to the expansion of these tools for the evaluation of patient well-
being in lower income countries, as demonstrated recently by their successful 
implementation in Cameroon (20). 
 
It would be unethical not to develop research on quality of life and patient perception of  ART 
in developing settings, especially in sub-Saharan Africa. If “do no harm” remains the main 
principle of all medicine, the integration of quality of life assessment in comprehensive 
research programs on HIV care is a major ethical and public health priority.   
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